Enter inventor name

Philipp Lustenberger

This inventor holds 48 USPTO granted patents, plus 3 CIPO patents and 3 EPO patents, primarily in CGRP Antagonists. Top assignees: Boehringer Ingelheim International Gmbh, Boehringer Ingelheim Pharma Gmbh & Co Kg, Novartis Ag. Active years: 2006-2023.

USPTO Granted Patents = 48

% Patents Active = 89.6

CIPO Patents = 3

EPO Patents = 3 (Patent Applications = 1)

Average Co-Inventor Count = 7.4

ph-index = 9

Forward Citations = 250(Granted Patents)

Location History:

Warthausen, DE (2006 - 2010)
Basel, CH (2007 - 2020)
Allschwil, CH (2013 - 2023)

Company Filing History:

31 out of 1,560

Boehringer Ingelheim International Gmbh

patents

10 out of 194

Boehringer Ingelheim Pharma Gmbh & Co Kg

4. 1 out of 834,350

Other

patents

Years Active: 2006-2023

Loading Chart...

Areas of Expertise:

CGRP Antagonists

Bronchodilators

MCH Antagonistic Compounds

Beta Agonists

Medicaments

Pharmaceutical Compositions

Crystalline Form

Benzothiazolone Compounds

Alkyne Compounds

Enantiomerically Pure

Beta-2-Agonists

Substituted Piperidines

48 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11603363 - Crystalline form of LNP023 (2023-03-14),

2. 10723735 - Process for preparing 1-(4-methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo [2,3-B]pyridin-3-yl-acetic acid (2020-07-28),

3. 10508110 - Process for preparing 1-(4-methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo [2,3-B]pyridin-3-yl-acetic acid (2019-12-17),

4. 10251868 - Benzothiazolone compound (2019-04-09),

5. 9913828 - Benzothiazolone compound (2018-03-13),

6. 8933108 - Benzothiazolone compound (2015-01-13),

7. 8618132 - Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds (2013-12-31),

8. 8084487 - Processes for the preparation of 4-oxo-octahydro-indole-1-carbocyclic acid methyl ester and derivatives thereof (2011-12-27),

9. 8044046 - Medicaments for the treatment of chronic obstructive pulmonary disease (2011-10-25),

10. 8034809 - Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments (2011-10-11),

11. 7985747 - Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions (2011-07-26),

12. 7897603 - Selected CGRP-antagonists, processes for preparing them and their use as pharmaceutical compositions (2011-03-01),

13. 7858622 - Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions (2010-12-28),

14. 7786111 - Medicaments for the treatment of chronic obstructive pulmonary disease (2010-08-31),

15. 7745621 - Long acting bronchodilators for the treatment of respiratory diseases (2010-06-29),

Certainly! Here is the article about inventor Philipp Lustenberger based on the provided data:

Title: Unveiling the Innovations of Philipp Lustenberger

Introduction:

Philipp Lustenberger, a prolific inventor hailing from Warthausen, Germany, has made significant contributions in the field of pharmaceuticals and novel synthesis processes. With an impressive portfolio of 48 patents to his name, his work continues to shape the landscape of drug development and treatment methodologies.

Latest Patents:

Lustenberger's recent advancements include the crystalline hydrate form of LNP023 hydrochloride, showcasing a revolutionary pharmaceutical composition tailored to treat diseases and disorders mediated by complement activation. Additionally, his innovative process for preparing 1-(4-methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo[2,3-B]pyridin-3-yl-acetic acid has opened new avenues in the realm of novel synthesis techniques.

Career Highlights:

Having traversed the corridors of renowned institutions, Philipp Lustenberger has left an indelible mark during his tenure at Boehringer Ingelheim International GmbH and Boehringer Ingelheim Pharma GmbH & Co. KG. His strategic insights and groundbreaking innovations have played a pivotal role in elevating the standards of research and development within the pharmaceutical industry.

Collaborations:

Throughout his illustrious career, Philipp Lustenberger has collaborated closely with esteemed professionals in the field, including Klaus Rudolf and Stephan Georg Mueller. Together, they have synergized their expertise to drive forward innovative solutions and redefine the boundaries of pharmaceutical sciences.

Conclusion:

In conclusion, Philipp Lustenberger stands as a stalwart figure in the realm of inventions, with a keen focus on pioneering pharmaceutical compositions and synthesis processes. His unwavering dedication to advancing healthcare solutions underscores his commitment to creating a positive impact on society, making him a trailblazer in the world of innovation and patents.

I hope you find this article insightful and informative! If you need any more assistance or information, feel free to ask.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to [email protected]